Search results
Sandoz is a global leader in generic pharmaceuticals and biosimilars, with a mission to discover new ways to improve and extend people's lives. Learn more about our products, our quality standards, our innovation and sustainability efforts, and our partnerships and collaborations.
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
Explore the products that Sandoz US offers to patients and customers, including generic and biosimilar medicines for various health needs.
Oct 4, 2023 · Sandoz planned spin-off updates at Novartis Q2 2023 Financial Results. The Novartis Board of Directors has unanimously endorsed the proposed separation of Sandoz to create an independent company by way of a 100% spin-off.
Oct 4, 2023 · Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off. Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange.
Sandoz today is the leading global provider of off-patent medicines (biosimilars and generics), which account for approximately 80% of medicines used worldwide at a fraction of the total cost.
Mar 5, 2024 · Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than...
